MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says

MT Newswires Live08-07

MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with 2026 being a "year of execution" on the commercial and clinical fronts, Wedbush said in a Thursday note.

The company plans to prioritize its Furoscix therapy, with its ReadyFlow autoinjector delivery system priced at around the same level as the on-body infusor but with a 70% higher gross margin, the firm said. MannKind stated that 2026 total net revenue could be nearer to the lower end of guidance of $110 million, but the inventory buying pattern may impact H2 revenue significantly, according to the note.

MannKind's partner United Therapeutics (UTHR) expects future demand for ralinepag DPI and Tyvaso DPI to require all of its manufacturing capacity, pointing to strong revenue potential, Wedbush said.

Further, MannKind plans to focus on the pediatric market in the near term for Afrezza after the drug's approval from the US Food and Drug Administration in May, the firm said.

Wedbush's rating on the company's stock is outperform with a price target of $8.

Price: 3.81, Change: -0.29, Percent Change: -7.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657865612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 00:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657865612","market":"nz","top_or_hot":-1,"title":"MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with 2026 being a \"year of execution\" on the commercial and clinical fronts, Wedbush said in a Thursday note.</p><p>The company plans to prioritize its Furoscix therapy, with its ReadyFlow autoinjector delivery system priced at around the same level as the on-body infusor but with a 70% higher gross margin, the firm said. MannKind stated that 2026 total net revenue could be nearer to the lower end of guidance of $110 million, but the inventory buying pattern may impact H2 revenue significantly, according to the note.</p><p>MannKind's partner United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UTHR) expects future demand for ralinepag DPI and Tyvaso DPI to require all of its manufacturing capacity, pointing to strong revenue potential, Wedbush said.</p><p>Further, MannKind plans to focus on the pediatric market in the near term for Afrezza after the drug's approval from the US Food and Drug Administration in May, the firm said.</p><p>Wedbush's rating on the company's stock is outperform with a price target of $8.</p><p>Price: 3.81, Change: -0.29, Percent Change: -7.07</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-07 00:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with 2026 being a \"year of execution\" on the commercial and clinical fronts, Wedbush said in a Thursday note.</p><p>The company plans to prioritize its Furoscix therapy, with its ReadyFlow autoinjector delivery system priced at around the same level as the on-body infusor but with a 70% higher gross margin, the firm said. MannKind stated that 2026 total net revenue could be nearer to the lower end of guidance of $110 million, but the inventory buying pattern may impact H2 revenue significantly, according to the note.</p><p>MannKind's partner United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UTHR) expects future demand for ralinepag DPI and Tyvaso DPI to require all of its manufacturing capacity, pointing to strong revenue potential, Wedbush said.</p><p>Further, MannKind plans to focus on the pediatric market in the near term for Afrezza after the drug's approval from the US Food and Drug Administration in May, the firm said.</p><p>Wedbush's rating on the company's stock is outperform with a price target of $8.</p><p>Price: 3.81, Change: -0.29, Percent Change: -7.07</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657865612","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657865612","pubTimestamp":1786033673,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MannKind's  increasingly diversified portfolio is seen bringing in higher revenue in H2, with 2026 being a \"year of execution\" on the commercial and clinical fronts, Wedbush said in a Thursday note.The company plans to prioritize its Furoscix therapy, with its ReadyFlow autoinjector delivery system priced at around the same level as the on-body infusor but with a 70% higher gross margin, the firm said. MannKind stated that 2026 total net revenue could be nearer to the lower end of guidance of $110 million, but the inventory buying pattern may impact H2 revenue significantly, according to the note.MannKind's partner United Therapeutics  expects future demand for ralinepag DPI and Tyvaso DPI to require all of its manufacturing capacity, pointing to strong revenue potential, Wedbush said.Further, MannKind plans to focus on the pediatric market in the near term for Afrezza after the drug's approval from the US Food and Drug Administration in May, the firm said.Wedbush's rating on the compa","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"Wedbush 表示，MannKind 的多元化投资组合预计将导致下半年收入增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with 2026 being a \"year of execution\" on the commercial and clinical fronts, Wedbush said in a Thursday note.The company plans to prioritize its Furoscix therapy, with its ReadyFlow autoinjector delivery system priced at around the same level as the on-body infusor but with a 70% higher gross margin, the firm said. MannKind stated that 2026 total net revenue could be nearer to the lower end of guidance of $110 million, but the inventory buying pattern may impact H2 revenue significantly, according to the note.MannKind's partner United Therapeutics (UTHR) expects future demand for ralinepag DPI and Tyvaso DPI to require all of its manufacturing capacity, pointing to strong revenue potential, Wedbush said.Further, MannKind plans to focus on the pediatric market in the near term for Afrezza after the drug's approval from the US Food and Drug Administration in May, the firm said.Wedbush's rating on the company's stock is outperform with a price target of $8.Price: 3.81, Change: -0.29, Percent Change: -7.07","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657865612","isCrawlerRequest":true}